Suppr超能文献

Myc的治疗靶点

Therapeutic Targeting of Myc.

作者信息

Prochownik Edward V, Vogt Peter K

机构信息

Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Pittsburgh, PA.

出版信息

Genes Cancer. 2010 Jun;1(6):650-659. doi: 10.1177/1947601910377494.

Abstract

Protein-protein interactions between members of the Myc transcription factor network are potential targets of small molecule inhibitors and stabilizers. Diverse screening strategies, including fluorescence resonance energy transfer, fluorescence polarization, two hybrid and protein complementation assays have identified several lead compounds that inhibit Myc-Max dimerization and one compound that stabilizes the Max homodimer. Representative compounds interfere with Myc-induced transcriptional activation, Myc-mediated oncogenic transformation, Myc-driven cellular replication and DNA binding of Myc. For the best characterized compounds, specific binding sites have been determined, and molecular mechanisms of action have been documented. This knowledge of small molecule - protein interaction is currently applied to highly targeted approaches that seek to identify novel compounds with improved potency.

摘要

Myc转录因子网络成员之间的蛋白质-蛋白质相互作用是小分子抑制剂和稳定剂的潜在靶点。多种筛选策略,包括荧光共振能量转移、荧光偏振、双杂交和蛋白质互补分析,已经鉴定出几种抑制Myc-Max二聚化的先导化合物以及一种稳定Max同型二聚体的化合物。代表性化合物可干扰Myc诱导的转录激活、Myc介导的致癌转化、Myc驱动的细胞复制以及Myc的DNA结合。对于特征最明确的化合物,已经确定了其特异性结合位点,并记录了其分子作用机制。目前,这种小分子-蛋白质相互作用的知识已应用于高度靶向的方法,以寻找具有更高效力的新型化合物。

相似文献

1
Therapeutic Targeting of Myc.
Genes Cancer. 2010 Jun;1(6):650-659. doi: 10.1177/1947601910377494.
2
Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.
Mol Pharmacol. 2009 Sep;76(3):491-502. doi: 10.1124/mol.109.054858. Epub 2009 Jun 4.
3
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3830-5. doi: 10.1073/pnas.062036999. Epub 2002 Mar 12.
4
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
Cell Chem Biol. 2019 May 16;26(5):711-723.e14. doi: 10.1016/j.chembiol.2019.02.009. Epub 2019 Mar 14.
5
In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.
Oncotarget. 2014 Oct 15;5(19):8869-78. doi: 10.18632/oncotarget.2588.
6
Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Eur J Med Chem. 2018 Dec 5;160:108-119. doi: 10.1016/j.ejmech.2018.09.023. Epub 2018 Sep 11.
8
Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules.
Chem Biol. 2006 Jul;13(7):745-51. doi: 10.1016/j.chembiol.2006.05.011.
9
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Bioorg Med Chem. 2021 Sep 1;45:116324. doi: 10.1016/j.bmc.2021.116324. Epub 2021 Jul 22.

引用本文的文献

1
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response.
Proc Natl Acad Sci U S A. 2025 Jun 10;122(23):e2420011122. doi: 10.1073/pnas.2420011122. Epub 2025 Jun 2.
2
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.
Signal Transduct Target Ther. 2024 Dec 6;9(1):341. doi: 10.1038/s41392-024-02036-3.
3
Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.
J Cancer Res Clin Oncol. 2024 Sep 20;150(9):426. doi: 10.1007/s00432-024-05939-4.
4
Overcoming phenotypic switching: targeting protein-protein interactions in cancer.
Explor Target Antitumor Ther. 2023;4(5):1071-1081. doi: 10.37349/etat.2023.00181. Epub 2023 Oct 30.
5
A Novel Transgenic Mouse Model Implicates as a Promoter of Hepatocellular Carcinoma.
Int J Mol Sci. 2023 Aug 9;24(16):12618. doi: 10.3390/ijms241612618.
6
Lessons in aging from Myc knockout mouse models.
Front Cell Dev Biol. 2023 Aug 9;11:1244321. doi: 10.3389/fcell.2023.1244321. eCollection 2023.
7
Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation.
Cell Rep. 2023 Aug 29;42(8):112830. doi: 10.1016/j.celrep.2023.112830. Epub 2023 Jul 22.
8
Strategies to target the cancer driver MYC in tumor cells.
Front Oncol. 2023 Mar 8;13:1142111. doi: 10.3389/fonc.2023.1142111. eCollection 2023.
9
Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
Cells. 2022 Dec 22;12(1):37. doi: 10.3390/cells12010037.

本文引用的文献

3
Protein intrinsic disorder and oligomericity in cell signaling.
Mol Biosyst. 2010 Mar;6(3):451-61. doi: 10.1039/b916030m. Epub 2009 Nov 3.
4
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928.
5
6
Emerging Raf inhibitors.
Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633.
7
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
8
Regulated cell death pathways: new twists in modulation of BCL2 family function.
Mol Cancer Ther. 2009 Jun;8(6):1421-9. doi: 10.1158/1535-7163.MCT-08-0895. Epub 2009 Jun 9.
9
BRAF signaling and targeted therapies in melanoma.
Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001.
10
Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.
J Am Chem Soc. 2009 Jun 3;131(21):7390-401. doi: 10.1021/ja900616b.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验